New Paradigms for HER2-Positive Early Breast Cancer: Implications and Application

Program Overview

Trastuzumab Improves DFS by 40%-50%

Trastuzumab Improves OS by 33%

Could We Give Less? The APT Trial

Study Design: APT Trial

APT Trial: 3-Year and 7-Year DFS Follow-Up

BCIRG-006: 10-Year Follow-Up Analysis

Disease-Free Survival (10.3 years)

Overall Survival (10.3 years)

HERA Trial Final Analysis (10-Year Follow-Up)

Standard Adjuvant Therapeutic Options in Early-Stage HER2-Positive Disease

APHINITY Trial

APHINITY Trial Design

Intent-to-Treat Primary Endpoint Analysis IDFS

APHINITY: IDFS Forest Plot by Subgroups

APHINITY Trial: Applying the Data to Clinical Practice

APHINITY Trial: Take-Home Messages

Could You Give More? Escalating Treatment in HER2-Positive EBC ExteNET Trial data

ExteNET Trial: Study Schema

ExteNET Trial Results: IDFS

ExteNET Trial Results: Subgroups

ExteNET Trial: Safety Data

ExteNET Trial: Conclusions

ExteNET Trial: Applying the Data to Clinical Practice

Concluding Remarks

Concluding Remarks, Cont’d

Abbreviations

Abbreviations (cont)